News | May 29, 2024
IGC Pharma announces patient enrollment at Neurostudies in Phase 2 trial investigating IGC-AD1
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Launch of 20 new medicines expected by 2030
_256_384.jpeg)
ASG Group of Eye Hospitals has 165+ branches in 85+ cities across India and abroad
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA before special items falls 1.3 percent to € 4.41 billion
Lupin updates on shipment of Mirabegron ER Tablets
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Subscribe To Our Newsletter & Stay Updated
